Zhitong Finance App News, Shiyao Group (01093.HK) announced that the midterm analysis results of the phase III clinical study (study number: HEALER) of anituzumab injection (trade name: Eniturum®) co-injectable docetaxel (albumin binding) (HB1801) for first-line treatment of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (study number: HEALER) were selected on October 24, 2026 at the 2026 European Society of Medical Oncology (ESMO) Annual Meeting The latest breakthrough abstract (LBA) is presented in the form of a selected oral report. At the same time, the study was simultaneously published in the “New England Journal of Medicine” (NEJM) in the form of an original paper, making it the first result published in NEJM in the clinical field of breast cancer in mainland China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.